Biggest Manufacturer， Neratinib（698387-09-6） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

WEB: www.eosmedchem.com

EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  

TEL: 0086-531-69905422

GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.
 Neratinib, CAS#698387-09-6, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 55 KG in stock, pls check:

Name: Neratinib
CAS#: 698387-09-6
Formula: C30H29ClN6O3
Exact Mass: 556.19897 
Molecular Weight: 557.04 
Elemental Analysis:  C, 64.68; H, 5.25; Cl, 6.36; N, 15.09; O, 8.62
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)

2. 
Intermediates:

1. Neratinib Intermediate:N-(4-chloro-3-cyano-7-ethoxy-1,4-dihydroquinolin-6-yl)acetamide
Cas# 848133-76-6
We have more than 75 kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

2.Neratinib Intermediate:4-((pyridin-2-yl)methoxy)-3-chlorobenzenamine
Cas# 524955-09-7
We have more than 70 kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

References：

1: Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, Cortés J, Kiger C, Germa C, Wang K, Martin M, Baselga J, Kim SB. Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2014 Oct 6. pii: JCO.2014.56.3809. [Epub ahead of print] PubMed PMID: 25287822.
2: Schwab CL, English DP, Roque DM, Bellone S, Lopez S, Cocco E, Nicoletti R, Rutherford TJ, Schwartz PE, Santin AD. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol. 2014 Oct;135(1):142-8. doi: 10.1016/j.ygyno.2014.08.006. Epub 2014 Aug 12. PubMed PMID: 25124161.
3: Neratinib Graduates to I-SPY 3. Cancer Discov. 2014 Jun;4(6):624. doi: 10.1158/2159-8290.CD-NB2014-055. Epub 2014 Apr 7. PubMed PMID: 24891343.
4: Zhang X, Munster PN. New protein kinase inhibitors in breast cancer: afatinib and neratinib. Expert Opin Pharmacother. 2014 Jun;15(9):1277-88. doi: 10.1517/14656566.2014.913570. Epub 2014 Apr 30. PubMed PMID: 24787047.
5: Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, Hollebecque A, Abbas R, Ananthakrishnan R, Berkenblit A, Krygowski M, Liang Y, Turnbull KW, Shapiro GI, Soria JC. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol. 2014 Jan 10;32(2):68-75. doi: 10.1200/JCO.2012.47.2787. Epub 2013 Dec 9. PubMed PMID: 24323026.
6: Jankowitz RC, Abraham J, Tan AR, Limentani SA, Tierno MB, Adamson LM, Buyse M, Wolmark N, Jacobs SA. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2 positive breast cancer: an NSABP Foundation Research Program phase I study. Cancer Chemother Pharmacol. 2013 Dec;72(6):1205-12. PubMed PMID: 24077916.
7: Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013 Oct;4(10):1592-605. PubMed PMID: 24009064; PubMed Central PMCID: PMC3858548.
8: Martin M, Bonneterre J, Geyer CE Jr, Ito Y, Ro J, Lang I, Kim SB, Germa C, Vermette J, Wang K, Wang K, Awada A. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer. 2013 Dec;49(18):3763-72. doi: 10.1016/j.ejca.2013.07.142. Epub 2013 Aug 15. PubMed PMID: 23953056.
9: Chow LW, Xu B, Gupta S, Freyman A, Zhao Y, Abbas R, Vo Van ML, Bondarenko I. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer. 2013 May 28;108(10):1985-93. doi: 10.1038/bjc.2013.178. Epub 2013 Apr 30. PubMed PMID: 23632474; PubMed Central PMCID: PMC3670493.
10: Awada A, Dirix L, Manso Sanchez L, Xu B, Luu T, Diéras V, Hershman DL, Agrapart V, Ananthakrishnan R, Staroslawska E. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2013 Jan;24(1):109-16. doi: 10.1093/annonc/mds284. Epub 2012 Sep 11. PubMed PMID: 22967996.

Biggest Manufacturer，Obeticholic acid（459789-99-2） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

WEB: www.eosmedchem.com

EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  

TEL: 0086-531-69905422

GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Obeticholic acid, CAS#459789-99-2, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 1KG in stock, pls check:

Name:Obeticholic acid

CAS#: 459789-99-2

Formula: C26H44O4 

Exact Mass: 420.32396 

Molecular Weight: 420.63

Elemental Analysis: C, 74.24; H, 10.54; O, 15.21

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Obeticholic Intermediates:

1. 3α-Hydroxy-7-Oxo-5β-Cholanic Acid

cas#4651-67-6

we have more than 14kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

2.3α-hydroxy-6-ethylidene-7-oxo-5β-cholanoic acid

 cas#1516887-33-4

we have more than 23kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

3.3α-hydroxy-6α-ethyl-7-oxo-5β-cholanoic acid

Cas#915038-26-5 

We have more than 19kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

4.7-ketolithocholic Methyl ester

Cas#10538-59-7

We have more than 21kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

5. (EZ)-3-hydroxy-6-ethylidene-7-keto-5-cholan-24-oic acid methyl ester

Cas#863239-59-2 

We have more than 19kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

6.Obeticholic acid Intermediate

Cas#1953137-50-2

We have more than 17kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

7.Obeticholic acid Intermediate

Cas# 1227612-51-2

We have more than 14kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

8.Obeticholic acid Intermediate

Cas#2124210-49-5

We have more than 23kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

References

1: Armstrong MJ, Newsome PN. Trials of obeticholic acid for non-alcoholic steatohepatitis. Lancet. 2015 Jul 4;386(9988):28. doi: 10.1016/S0140-6736(15)61199-0. PubMed PMID: 26169862.

2: Neuschwander-Tetri BA, Van Natta ML, Tonascia J, Brunt EM, Kleiner DE. Trials of obeticholic acid for non-alcoholic steatohepatitis - Authors' reply. Lancet. 2015 Jul 4;386(9988):28-9. doi: 10.1016/S0140-6736(15)61200-4. PubMed PMID: 26169861.

3: Musso G, Cassader M, Gambino R. Trials of obeticholic acid for non-alcoholic steatohepatitis. Lancet. 2015 Jul 4;386(9988):27. doi: 10.1016/S0140-6736(15)61198-9. PubMed PMID: 26169860.

4: Dong R, Zheng S, Chen G. The Appropriate Timing and Dose of Obeticholic Acid in Patients With Primary Biliary Cirrhosis. Gastroenterology. 2015 Aug;149(2):508. doi: 10.1053/j.gastro.2015.01.050. Epub 2015 Jun 29. PubMed PMID: 26136168.

5: Arrese M, Cabrera D, Barrera F. Obeticholic acid: expanding the therapeutic landscape of NASH. Ann Hepatol. 2015 May-Jun;14(3):430-2. PubMed PMID: 25864227.

6: Musso G. Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost. Hepatology. 2015 Jun;61(6):2104-6. doi: 10.1002/hep.27772. Epub 2015 Apr 8. PubMed PMID: 25753820.

7: Wong VW, Wong GL, Chan FK. Is obeticholic Acid the solution to nonalcoholic steatohepatitis? Gastroenterology. 2015 Apr;148(4):851-2. doi: 10.1053/j.gastro.2015.02.044. Epub 2015 Feb 26. PubMed PMID: 25726736.

8: Verbeke L, Farre R, Verbinnen B, Covens K, Vanuytsel T, Verhaegen J, Komuta M, Roskams T, Chatterjee S, Annaert P, Vander Elst I, Windmolders P, Trebicka J, Nevens F, Laleman W. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol. 2015 Feb;185(2):409-19. doi: 10.1016/j.ajpath.2014.10.009. Epub 2015 Jan 12. PubMed PMID: 25592258.

9: Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC Jr, Parés A, Trauner M, Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelloe E, Böhm O, Shapiro D. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015 Apr;148(4):751-61.e8. doi: 10.1053/j.gastro.2014.12.005. Epub 2014 Dec 11. PubMed PMID: 25500425.

10: Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7. Erratum in: Lancet. 2015 Mar 14;385(9972):946. PubMed PMID: 25468160; PubMed Central PMCID: PMC4447192.

Biggest Manufacturer, Palbociclib （571190-30-2) and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

2018 Korea CPHI, C30 

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

WEB: www.eosmedchem.com

EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  

TEL: 0086-531-69905422

GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Palbociclib, CAS#571190-30-2, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 1KG in stock, pls check:

Name: Palbociclib

CAS#: 571190-30-2

Formula:C24H29N7O2 

Exact Mass: 447.23827 

Molecular Weight: 447.543 

Elemental Analysis: C, 64.41; H, 6.53; N, 21.91; O, 7.15

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Palbociclib Intermediates:

1. Ponatinib Intermediate:4-(6-Aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester

cas#571188-59-5

we have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

2.Ponatinib Intermediate:2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one

cas#1013916-37-4

we have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

3.Ponatinib Intermediate:6-bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one

cas#1016636-76-2

we have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

References

1: Badia R, Angulo G, Riveira-Muñoz E, Pujantell M, Puig T, Ramirez C, Torres-Torronteras J, Martí R, Pauls E, Clotet B, Ballana E, Esté JA. Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1. J Antimicrob Chemother. 2015 Nov 4. pii: dkv363. [Epub ahead of print] PubMed PMID: 26542306.

2: Qin G, Xu F, Qin T, Zheng Q, Shi D, Xia W, Tian Y, Tang Y, Wang J, Xiao X, Deng W, Wang S. Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway. Oncotarget. 2015 Oct 19. doi: 10.18632/oncotarget.5993. [Epub ahead of print] PubMed PMID: 26540629.

3: Ozaki A, Tanimoto T, Saji S. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Oct 22;373(17):1672-3. doi: 10.1056/NEJMc1510345#SA1. PubMed PMID: 26488701.

4: Turner NC, Huang Bartlett C, Cristofanilli M. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Oct 22;373(17):1672-3. doi: 10.1056/NEJMc1510345. PubMed PMID: 26488700.

5: Solimando DA Jr, Waddell JA. Lenvatinib and Palbociclib. Hosp Pharm. 2015 Jul;50(7):578-82. doi: 10.1310/hpj5007-578. Epub 2015 Jul 31. PubMed PMID: 26448668; PubMed Central PMCID: PMC4589862.

6: Palbociclib Prolongs Progression-Free Survival in Patients with Advanced Breast Cancer. Am Health Drug Benefits. 2015 Aug;8(Spec Issue):36. PubMed PMID: 26380621; PubMed Central PMCID: PMC4570077.

7: Parrish KE, Pokorny J, Mittapalli RK, Bakken K, Sarkaria JN, Elmquist WF. Efflux Transporters at the Blood-Brain Barrier Limit Delivery and Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib (PD-0332991) in an Orthotopic Brain Tumor Model. J Pharmacol Exp Ther. 2015 Nov;355(2):264-71. doi: 10.1124/jpet.115.228213. Epub 2015 Sep 9. PubMed PMID: 26354993; PubMed Central PMCID: PMC4613960.

8: Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, Zirkelbach JF, Yu J, Liu Q, Zhao L, Crich J, Chen XH, Hughes M, Bloomquist E, Tang S, Sridhara R, Kluetz PG, Kim G, Ibrahim A, Pazdur R, Cortazar P. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2015 Nov 1;21(21):4760-6. doi: 10.1158/1078-0432.CCR-15-1185. Epub 2015 Aug 31. PubMed PMID: 26324739.

9: Mangini NS, Wesolowski R, Ramaswamy B, Lustberg MB, Berger MJ. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer. Ann Pharmacother. 2015 Nov;49(11):1252-60. doi: 10.1177/1060028015602273. Epub 2015 Aug 31. Review. PubMed PMID: 26324355.

10: Lu J. Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer. J Hematol Oncol. 2015 Aug 13;8:98. doi: 10.1186/s13045-015-0194-5. PubMed PMID: 26264704; PubMed Central PMCID: PMC4534142.

11: Palbociclib (Ibrance) for metastatic breast cancer. Med Lett Drugs Ther. 2015 Aug 17;57(1475):115-6. PubMed PMID: 26262882.

12: McCain J. First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer. P T. 2015 Aug;40(8):511-20. PubMed PMID: 26236140; PubMed Central PMCID: PMC4517534.

13: Carey LA, Perou CM. Palbociclib--Taking Breast-Cancer Cells Out of Gear. N Engl J Med. 2015 Jul 16;373(3):273-4. doi: 10.1056/NEJMe1506680. PubMed PMID: 26176385.

14: de Gooijer MC, Zhang P, Thota N, Mayayo-Peralta I, Buil LC, Beijnen JH, van Tellingen O. P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Invest New Drugs. 2015 Oct;33(5):1012-9. doi: 10.1007/s10637-015-0266-y. Epub 2015 Jul 1. PubMed PMID: 26123925.

15: Morikawa A, Henry NL. Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2015 Aug 15;21(16):3591-6. doi: 10.1158/1078-0432.CCR-15-0390. Epub 2015 Jun 22. PubMed PMID: 26100274; PubMed Central PMCID: PMC4537809.

16: Harding E. Palbociclib for hormone receptor-positive breast cancer. Lancet Oncol. 2015 Jul;16(7):e318. doi: 10.1016/S1470-2045(15)00032-7. Epub 2015 Jun 7. PubMed PMID: 26062777.

17: L'Allemain G. [Doubling time of progression-free survival by palbociclib in metastatic breast cancer]. Bull Cancer. 2015 Apr;102(4):300. doi: 10.1016/j.bulcan.2015.02.011. French. PubMed PMID: 26042255.

18: Palbociclib Extends Survival in Advanced Breast Cancer. Cancer Discov. 2015 Jul;5(7):OF5. doi: 10.1158/2159-8290.CD-NB2015-083. Epub 2015 Jun 2. PubMed PMID: 26036642.

19: Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M; PALOMA3 Study Group. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1. PubMed PMID: 26030518.

20: Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S, Spicka I, Chanan-Khan AA, Raab MS, Tarantolo S, Vij R, Zonder JA, Huang X, Jayabalan D, Di Liberto M, Huang X, Jiang Y, Kim ST, Randolph S, Chen-Kiang S. Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leuk Lymphoma. 

Biggest Manufacturer，Encorafenib (1269440-17-6 ) and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

                                                           2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

WEB: www.eosmedchem.com

EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  

TEL: 0086-531-69905422

GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Encorafenib, CAS#1269440-17-6, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 1KG in stock, pls check:

Name: Encorafenib

CAS#: 1269440-17-6,

Formula: C22H27ClFN7O4S

Exact Mass: 539.15178 

Molecular Weight: 540.01 

Elemental Analysis: C, 48.93; H, 5.04; Cl, 6.57; F, 3.52; N, 18.16; O, 11.85; S, 5.94

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2.

Encorafenib Intermediates:

1.Tert-butyl 5-chloro-2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylcarbamate, cas#1269440-69-8, we have more than 1kg in stock, assay 99% in GMP plant, CGMP standard, now COA, NMR, HPLC, MS is ok.

 2.(S)-methyl (1-aminopropan-2-yl)carbamate, cas#1229025-89-1, we have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

3.methyl N-[(2S)-1-aminopropan-2-yl]carbamate,hydrochloride,

 cas#1229025-32-4, we have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

4.2-chloro-4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidine,

 cas#1269440-58-5, we have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

5.(S)-methyl 1-(4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate

 cas#1269440-60-9, we have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

6.Tert-butyl 3-bromo-5-chloro-2-fluorophenyl-carbamate,

 cas#1269232-94-1, we have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

References

1: Niessner H, Sinnberg T, Kosnopfel C, Smalley KSM, Beck D, Praetorius C, Mai M, Beissert S, Kulms D, Schaller M, Garbe C, Flaherty KT, Westphal D, Wanke I, Meier F. BRAF inhibitors amplify the pro-apoptotic activity of MEK inhibitors by inducing ER stress in NRAS-mutant melanoma. Clin Cancer Res. 2017 Jul 19. pii: clincanres.0098.2017. doi: 10.1158/1078-0432.CCR-17-0098. [Epub ahead of print] PubMed PMID: 28724666.

2: Maanaoui M, Saint-Jacques C, Gnemmi V, Frimat M, Lionet A, Hazzan M, Noël C, Provot F. Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: A case report. Medicine (Baltimore). 2017 Jun;96(25):e7196. doi: 10.1097/MD.0000000000007196. PubMed PMID: 28640105; PubMed Central PMCID: PMC5484213.

3: Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan RJ, Arance A, Kefford RF, Carlino MS, Hidalgo M, Gomez-Roca C, Michel D, Seroutou A, Aslanis V, Caponigro G, Stuart D, Moutouh-de Parseval L, Demuth T, Dummer R. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. Clin Cancer Res. 2017 Jun 13. pii: clincanres.2923.2016. doi: 10.1158/1078-0432.CCR-16-2923. [Epub ahead of print] PubMed PMID: 28611198.

4: Grimaldi AM, Simeone E, Festino L, Vanella V, Strudel M, Ascierto PA. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors. Am J Clin Dermatol. 2017 May 23. doi: 10.1007/s40257-017-0292-y. [Epub ahead of print] Review. PubMed PMID: 28537004.

5: van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discov. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31. PubMed PMID: 28363909; PubMed Central PMCID: PMC5546207.

6: Turner MC, Rossfeld K, Salama AK, Tyler D, Beasley G. Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment? Expert Opin Pharmacother. 2017 Apr;18(5):487-495. doi: 10.1080/14656566.2017.1299710. Epub 2017 Mar 22. Review. PubMed PMID: 28277830.

7: Pascual LL, Muruzàbal RS, Gigli ML, Bayona JI. Cutaneous toxicity of a new BRAF inhibitor, LGX818 (encorafenib). Indian J Dermatol Venereol Leprol. 2017 Jan-Feb;83(1):102-104. doi: 10.4103/0378-6323.191130. PubMed PMID: 27679406.

8: Sparidans RW, Rosing H, Rood JJ, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:390-8. doi: 10.1016/j.jchromb.2016.09.012. Epub 2016 Sep 11. PubMed PMID: 27639128.

9: Asati V, Bharti SK, Mahapatra DK. Mutant B-Raf Kinase Inhibitors as Anticancer Agents. Anticancer Agents Med Chem. 2016;16(12):1558-1575. Review. PubMed PMID: 27264268.

10: Masuishi T, Muro K. [Current Progress and Feasibility of Using Molecular-Targeted Agent Combinations for Metastatic Colorectal Cancer]. Gan To Kagaku Ryoho. 2016 Apr;43(4):408-12. Japanese. PubMed PMID: 27220786.

11: Henning B, Stieger P, Kamarachev J, Dummer R, Goldinger SM. Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activation. Melanoma Res. 2016 Jun;26(3):304-7. doi: 10.1097/CMR.0000000000000248. PubMed PMID: 27116335.

12: Adelmann CH, Ching G, Du L, Saporito RC, Bansal V, Pence LJ, Liang R, Lee W, Tsai KY. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget. 2016 May 24;7(21):30453-60. doi: 10.18632/oncotarget.8351. PubMed PMID: 27028853; PubMed Central PMCID: PMC5058692.

13: Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res. 2016 Apr 1;22(7):1592-602. doi: 10.1158/1078-0432.CCR-15-1762. Epub 2015 Dec 16. PubMed PMID: 26673799; PubMed Central PMCID: PMC4818716.

14: Li Z, Jiang K, Zhu X, Lin G, Song F, Zhao Y, Piao Y, Liu J, Cheng W, Bi X, Gong P, Song Z, Meng S. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016 Jan 28;370(2):332-44. doi: 10.1016/j.canlet.2015.11.015. Epub 2015 Nov 14. PubMed PMID: 26586345.

15: Ascierto PA, Marincola FM, Atkins MB. What's new in melanoma? Combination! J Transl Med. 2015 Jul 4;13:213. doi: 10.1186/s12967-015-0582-1. PubMed PMID: 26141621; PubMed Central PMCID: PMC4491255.

16: Sullivan R, LoRusso P, Boerner S, Dummer R. Achievements and challenges of molecular targeted therapy in melanoma. Am Soc Clin Oncol Educ Book. 2015:177-86. doi: 10.14694/EdBook_AM.2015.35.177. Review. PubMed PMID: 25993155.

17: Scartozzi M, Giampieri R, Aprile G, Iacono D, Santini D, dell'Aquila E, Silvestris N, Gnoni A, Bonotto M, Puzzoni M, Demurtas L, Cascinu S. The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors. Expert Rev Mol Diagn. 2015;15(8):979-87. doi: 10.1586/14737159.2015.1047346. Epub 2015 May 15. Review. PubMed PMID: 25975986.

18: Trinh VA, You Y, Hwu WJ. Treatment of BRAF-mutated advanced cutaneous melanoma. Chin Clin Oncol. 2014 Sep;3(3):28. doi: 10.3978/j.issn.2304-3865.2014.05.10. PubMed PMID: 25841454.

19: Galliker NA, Murer C, Kamarashev J, Dummer R, Goldinger SM. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. Eur J Dermatol. 2015 Apr;25(2):177-80. doi: 10.1684/ejd.2014.2512. PubMed PMID: 25788221.

20: Drug combo beneficial in colorectal cancer. Cancer Discov. 2015 Feb;5(2):102. doi: 10.1158/2159-8290.CD-NB2014-186. Epub 2014 Dec 19. PubMed PMID: 25656881.